In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kitov Pharmceuticals (KTOV – Research Report), with a price target of $12. The company’s shares closed on Friday at $1.25.
“Our assessment is based on a risk-adjusted net present value (rNPV) approach, which ascribes a $225M valuation to KIT-302 (U.S. trade name Consensi), using a 15% discount rate and 23% effective tax rate. This has risen from the prior $160M valuation based on the improved metrics of the deal with Coeptis vs. our original assumptions, which solely involved Kitov’s receipt of low double-digit royalties on net sales of Consensi from a partner. We also ascribe a $55M valuation to NT219, Kitov’s preclinical pipeline candidate, applying a 40% probability of success and 15% discount rate.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 38.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Kitov Pharmceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $12.
The company has a one-year high of $3.81 and a one-year low of $0.56. Currently, Kitov Pharmceuticals has an average volume of 2.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kitov Pharma Ltd. is a development stage biopharmaceutical company, which engages in drug development. The firm offers Consensi and NT219. Consensi is intended to treat osteoarthritis pain and hyper tension simultaneously, while NT219 is a cancer therapy drug that delivers anti-tumor effects and increasing survical in various cancer models.